Federal Grant Award Summary

Yale University received a $559,992 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded July 1, 2026, with an ultimate completion date of June 30, 2028. The research project, titled "Biological Role and Therapeutic Targeting of HLA Class I Antigen Processing Machinery Dysregulation in Human Non-Small Cell Lung Cancer Brain Metastases," will be conducted at Yale's New Haven, Connecticut campus. This award supports hypothesis-driven biomedical research designed to advance innovative medical solutions and transform healthcare outcomes, consistent with the DHA's mission to address critical health challenges through basic, applied, and advanced research initiatives.

The project delivers research and development services focused on understanding the mechanisms of HLA Class I antigen processing machinery dysregulation in the context of lung cancer brain metastases and identifying potential therapeutic targets. As a two-year initiative within the Military Medical Research and Development program, this award represents one component of the DHA's comprehensive portfolio supporting translational research, biomarker discovery, and therapeutic development across diverse medical domains relevant to military and public health priorities. The research will undergo the program's standard two-tier competitive review process, which emphasizes both technical merit and military relevance in advancing oncology and immunotherapy research.